Octoplus« Terug naar discussie overzicht

1. flosz 11 februari 2011 08:31

   auteur info

   •    flosz

     Lid sinds: 13 feb 2008

     Laatste bezoek: 01 jul 2024

   •    Aanbevelingen

     Ontvangen: 5298

     Gegeven: 2795

   •    Aantal posts: 7.005

   Events.
   
   Met dank @ patient! imode.iex.nl/forum/topic.asp?forum=18...
   **************
   
   18 February 2011
   Publication of OctoPlus' 2010 full year results
   
   14.03.2011 - 16.03.2011
   BIO-Europe Spring
   Milan, Italy
   Competitive Cooperation Through Strong Alliances and Partnerships
   The Dutch are famous for their ability to build broad coalitions and form strong strategic alliances whether to keep out high seas or to breed a competitive life science sector. The Netherlands is the most concentrated region in the world in terms of working to create economic and social value in life sciences and health:
   • with the highest concentration of knowledge institutes, public/private consortia, SMEs
   • with organized and documented patient groups in a small geographic region
   • with a strong connection between the academic organizations
   • with a leading scientific position
   • with an outstanding infrastructure from education to biobanks
   Collaboration is in our genes. This is also illustrated by the fact that five of the top ten European biotech-pharma partnerships involve Dutch SMEs. This session will elaborate on the opportunities the Netherlands can offer. Speakers from Dutch innovative SMEs will present their companies and products and the possibilities to cooperate with you.
   Speakers:
   • Roland Lageveen – CEO, IQ Corporation
   • Ada Kruisbeek – CEO, DC Prime
   • Herman Steen – CEO, BiOrion Technologies
   • Bastiaan de Leeuw – CEO, NovioGendix
   • Maurits Peverelli – Director Sales & Marketing, Polyganics Holding
   • Jos Raats – President and CEO, ModiQuest Research
   • Ad van Gorp – CEO, Lead Pharma Holding
   • Andy Lewin – Senior Manager Business Development, Octoplus
   • Remko Clasen – Business Development Manager, BAC
   • Ivor Hidding – Technical Account Manager, Winclove BIO Industries
   www.ebdgroup.com/bes/program/index.php
   
   29 March 2011
   Kempen Investor Conference in Brussels
   
   30.03.2011 - 31.03.2011
   SMi: Controlled Release
   London, UK
   31 maart, 2011
   Development and clinical production of microsphere formulations
   • The added value of controlled release drug delivery technologies
   • Success factors in the process development, scale-up and manufacturing of microsphere-based formulations
   • Case study: Phase II clinical proof of concept with a controlled release formulation of interferon alpha
   Gerben Moolhuizen, Chief Business Officer, Octo Plus.
   www.smi-online.co.uk/events/programme...
   
   31 March 2011
   BioCapital conference in Amsterdam
   
   15.05.2011 - 19.05.2011
   Liposomes
   Jerusalem, Israel
   
   23.05.2011 - 25.05.2011
   BioMed
   Tel Aviv, Israel
   
   20 May 2011
   Annual General Meeting of Shareholders in Leiden
   
   16.06.2011
   Biotech Outsourcing Strategies cmc event
   Copenhagen (Horsholm), Denmark
   
   27.06.2011 - 30.06.2011
   BIO 2011
   Washington, USA
   
   30.07.2011 - 03.08.2011
   Controlled Release Society Annual Meeting
   Washington (National Harbor), USA
   
   25.10.2011 - 27.10.2011
   CPhI / ICSE
   Frankfurt, Germany
   
   31.10.2011 - 02.11.2011
   BIO-Europe
   Dusseldorf, Germany
   
   
2. flosz 8 april 2011 08:12

   auteur info

   •    flosz

     Lid sinds: 13 feb 2008

     Laatste bezoek: 01 jul 2024

   •    Aanbevelingen

     Ontvangen: 5298

     Gegeven: 2795

   •    Aantal posts: 7.005

   OctoPlus' Annual General Meeting of Shareholders will be held on 20 May in Leiden
   
   08.04.2011, Leiden, the Netherlands
   OctoPlus N.V. (“OctoPlus” or the “Company”) (Euronext: OCTO) announces that its Annual General Meeting of Shareholders will be held at the Company’s headquarters in Leiden on 20 May 2011 at 2 PM CET. The agenda and other information regarding the AGM are available in the Investor Relations section on the Company’s website, www.octoplus.nl.
   
   The Annual Report is also available on the Company’s website. Hard copies of the report can be requested by sending an e-mail to Investor Relations at ir@octoplus.nl.
   
   For further information
   hugin.info/137076/R/1504604/439550.pdf
   
   Agenda: www.octoplus.nl/showdownload.cfm?obje...